SCHEMBL7548447

SCHEMBL7548447

CC(C)(C)OC(=O)N1CCN=C1C=C(c1cccc(C(F)(F)F)c1)c1ccc2ccccc2n1

nearest known ligand 0.51

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
CNR2 P34972 2/20 0.51
BACE1 P56817 1/20 0.41
ALDH1A1 P00352 2/20 0.38
GFER P55789 2/20 0.36
POLB P06746 2/20 0.35
KDM4E B2RXH2 1/20 0.35
CYP3A4 P08684 1/20 0.35
MAPT P10636 1/20 0.35
CTDSP1 Q9GZU7 1/20 0.35
TDP1 Q9NUW8 1/20 0.35
MGLL Q99685 1/20 0.35
MAP2K4 P45985 1/20 0.34
ADORA3 P0DMS8 1/20 0.34
TRPV4 Q9HBA0 1/20 0.34
LMNA P02545 1/20 0.34
HPGD P15428 1/20 0.34
PHGDH O43175 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7548444 1.00 CNR2 (0.51) CNR2BACE1ALDH1A1GFERPOLB
SCHEMBL7550909 0.72 CNR2 (0.55) CNR2ALDH1A1POLBKDM4ECYP3A4
SCHEMBL7550912 0.72 CNR2 (0.55) CNR2ALDH1A1POLBKDM4ECYP3A4
SCHEMBL7548089 0.69 CNR2 (1.00) CNR2ALDH1A1POLBKDM4ECYP3A4
SCHEMBL7549457 0.69 KMT2A (0.42) ALDH1A1KDM4ECYP3A4LMNAHPGD
SCHEMBL7549956 0.69 KMT2A (0.42) ALDH1A1KDM4ECYP3A4LMNAHPGD
SCHEMBL15567728 0.65 POLB (0.65) POLBMGLLLMNAHPGD
SCHEMBL3128835 0.63 CACNA1B (0.61) CNR2CYP3A4
SCHEMBL27315476 0.62 PARP14 (0.55) ALDH1A1POLBMAPTLMNAHPGD
SCHEMBL28552332 0.62 CNR2 (0.49) CNR2ALDH1A1KDM4EMAPTLMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20020132812-A1 Oral hypoglycaemic agents NOVO NORDISK A/S (DK) 2002-09-19 US disclosed
WO-2002038559-A1 1,3-DIAZAHETEROCYCLIC COMPOUNDS AND THEIR USE AS ORAL HYPOGLYCAEMIC AGENTS NOVO NORDISK A/S (DK) 2002-05-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020132812-A1 Oral hypoglycaemic agents SLC5A2, GPR119, SLC5A1 CNR2 2676/4885BACE1 3221/4885ALDH1A1 440/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.